CDDO-3P-Im
Based on 1 Customer Validation
CDDO-3P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-3P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model. CDDO-3P-Im is a orally active necroptosis inhibitor that can be used for the research of ischemia/reperfusion (I/R).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.19%
- CAS. Nr.: 1883650-95-0
- Formel: C39H46N4O3
- Molecular Weight:618.81
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | EC50 |
0.31 μM
Compound: 20
|
Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
|
[PMID: 33248849] |
| L929 | EC50 |
0.86 μM
Compound: 20
|
Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
|
[PMID: 33248849] |
CDDO-3P-Im (30-100 nM; 4 days) induces differentiation of U937 cells at 30 nM[1].
CDDO-3P-Im suppresses NO production in RAW264.7 cells with an IC50 of 4.3 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U937 cells
-
Concentration:30 nM, 100 nM
-
Incubation Time:4 days
-
Result:Induced differentiation of U937 cells at 30 nM.
CDDO-3P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo[1].
CDDO-3P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Seven week-old female A/J mice[1]
-
Dosage:50 mg/kg, 200 mg/kg
-
Administration:Diet; for 16 weeks
-
Result:Decreased the number, the size and the severity of tumors.
Chemical Information
-
CAS. Nr. 1883650-95-0
-
Appearance Solid
-
Molecular Weight 618.81
-
Formel C39H46N4O3
-
Color White to off-white
-
SMILES
CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H])[H])C)C(N4C=C(C5=CC=CN=C5)N=C4)=O)C)6C)7[H])C(C(C#N)=C[C@]7(C)C6=CC3=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 250 mg/mL (404.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. [Content Brief]
[2]. Yuanyuan Wang, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2020 Nov 21;113030. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6160 mL | 8.0800 mL | 16.1600 mL | 40.4001 mL |
| 5 mM | 0.3232 mL | 1.6160 mL | 3.2320 mL | 8.0800 mL | |
| 10 mM | 0.1616 mL | 0.8080 mL | 1.6160 mL | 4.0400 mL | |
| 15 mM | 0.1077 mL | 0.5387 mL | 1.0773 mL | 2.6933 mL | |
| 20 mM | 0.0808 mL | 0.4040 mL | 0.8080 mL | 2.0200 mL | |
| 25 mM | 0.0646 mL | 0.3232 mL | 0.6464 mL | 1.6160 mL | |
| 30 mM | 0.0539 mL | 0.2693 mL | 0.5387 mL | 1.3467 mL | |
| 40 mM | 0.0404 mL | 0.2020 mL | 0.4040 mL | 1.0100 mL | |
| 50 mM | 0.0323 mL | 0.1616 mL | 0.3232 mL | 0.8080 mL | |
| 60 mM | 0.0269 mL | 0.1347 mL | 0.2693 mL | 0.6733 mL | |
| 80 mM | 0.0202 mL | 0.1010 mL | 0.2020 mL | 0.5050 mL | |
| 100 mM | 0.0162 mL | 0.0808 mL | 0.1616 mL | 0.4040 mL |